Industry · Health Care · close of Oct 30, 2026
Biotechnology Stocks
238 US-listed biotechnology companies above our tradable floor ($5 and $1 million a day), largest first, with each one's stage, price and valuation after the close.
238
companies
60 (25%)
in a Stage 2 uptrend
+32.0%
3-month return, weighted by size
11 · 71 · 74
in Stage 1 · 3 · 4
Only the Stage 2 ones →Filter them in the screener →All Health Care stocks →Industry rotation →
Every biotechnology stock we cover
| Stock | Stage | Close | Day | 3 months | From high | RS | P/E | Yield | Market cap |
|---|---|---|---|---|---|---|---|---|---|
| VRTXVertex Pharmaceuticals | Stage 2, wk 18 | $558.88 | +3.5% | +18.7% | 0.0% | 78 | 31.0 | — | $142B |
| REGNRegeneron Pharmaceuticals | Stage 2, wk 9 | $927.89 | +13.3% | +22.4% | 0.0% | 83 | 20.3 | 0.47% | $96.0B |
| MRNAModerna | Stage 2, wk 18 | $221.72 | -0.5% | +302.1% | -9.8% | 99 | — | — | $88.5B |
| ARGXargenx | Stage 3, wk 1 | $892.87 | -0.6% | +7.5% | -15.7% | 60 | 33.4 | — | $56.1B |
| ONCBeOne Medicines | Stage 2, wk 10 | $370.33 | -0.3% | +18.0% | -4.8% | 67 | 68.4 | — | $42.1B |
| RVMDRevolution Medicines | Stage 3, wk 1 | $191.31 | +0.5% | +4.9% | -13.5% | 98 | — | — | $41.0B |
| RPRXRoyalty Pharma | Stage 2, wk 50 | $67.18 | +1.9% | +18.0% | 0.0% | 93 | 33.9 | 1.51% | $38.8B |
| GMABGenmab | Stage 2, wk 10 | $57.06 | +1.0% | +99.0% | -0.4% | 95 | 31.5 | — | $35.1B |
| ROIVRoivant Sciences | Stage 2, wk 65 | $36.91 | -1.6% | +10.8% | -11.7% | 94 | — | — | $26.7B |
| INSMInsmed | Stage 4, wk 2 | $112.58 | +0.9% | +14.4% | -46.7% | 32 | — | — | $24.7B |
| INCYIncyte | Stage 3, wk 2 | $120.39 | +3.1% | +1.7% | -7.3% | 78 | 14.9 | — | $24.5B |
| BNTXBioNTech | Stage 3, wk 1 | $88.17 | -1.1% | -4.4% | -26.1% | 43 | — | — | $22.1B |
| ALNYAlnylam Pharmaceuticals | Stage 4, wk 37 | $165.00 | -5.2% | -25.1% | -65.1% | 17 | 38.3 | — | $22.1B |
| EXELExelixis | Stage 2, wk 27 | $69.39 | +4.8% | +26.0% | 0.0% | 92 | 20.6 | — | $16.9B |
| ASNDAscendis Pharma | Stage 3, wk 6 | $251.27 | -0.7% | +3.2% | -9.3% | 71 | 18.6 | — | $16.5B |
| HALOHalozyme Therapeutics | Stage 2, wk 17 | $130.91 | -0.2% | +59.1% | -0.2% | 95 | 36.4 | — | $14.9B |
| BBIOBridgeBio Pharma | Stage 4, wk 3 | $74.95 | +6.0% | -6.3% | -16.9% | 63 | — | — | $14.6B |
| JAZZJazz Pharmaceuticals | Stage 3, wk 5 | $215.98 | +3.9% | -14.2% | -17.4% | 88 | 14.7 | — | $14.0B |
| SMMTSummit Therapeutics | Stage 1, wk 8 | $16.03 | -1.0% | +22.9% | -39.2% | 43 | — | — | $12.8B |
| TECHBio-Techne | Stage 2, wk 14 | $72.66 | -0.1% | +0.8% | -0.1% | 67 | 62.6 | 0.44% | $11.4B |
| BMRNBioMarin Pharmaceutical | Stage 3, wk 3 | $58.51 | +1.8% | -2.5% | -16.7% | 63 | 153.1 | — | $11.3B |
| KYMRKymera Therapeutics | Stage 2, wk 19 | $126.63 | +3.3% | +26.2% | -0.5% | 96 | — | — | $10.8B |
| TWSTTwist Bioscience | Stage 2, wk 40 | $152.78 | -11.9% | +51.2% | -25.5% | 99 | — | — | $10.1B |
| MDGLMadrigal Pharmaceuticals | Stage 4, wk 1 | $430.36 | -0.3% | -10.7% | -28.6% | 55 | — | — | $9.9B |
| KRYSKrystal Biotech | Stage 3, wk 6 | $332.29 | +2.4% | +6.3% | -12.1% | 92 | 40.1 | — | $9.8B |
| PCVXVaxcyte | Stage 2, wk 13 | $62.03 | -0.9% | +15.9% | -16.0% | 83 | — | — | $9.8B |
| CAICaris Life Sciences | Stage 2, wk 7 | $34.33 | -5.0% | +110.4% | -5.0% | 66 | 18.8 | — | $9.7B |
| PTGXProtagonist Therapeutics | Stage 3, wk 1 | $144.85 | +0.4% | +9.5% | -8.7% | 94 | 135.5 | — | $9.4B |
| TGTXTG Therapeutics | Stage 2, wk 26 | $61.18 | +5.3% | +32.5% | 0.0% | 93 | 19.3 | — | $9.4B |
| SYRESpyre Therapeutics | Stage 3, wk 6 | $96.56 | -2.4% | +1.7% | -11.3% | 99 | — | — | $9.0B |
| IBRXImmunityBio | Stage 2, wk 10 | $8.29 | -5.1% | +15.9% | -28.2% | 98 | — | — | $8.8B |
| CORTCorcept Therapeutics | Stage 3, wk 1 | $81.12 | -5.6% | -28.1% | -34.4% | 63 | 238.9 | — | $8.8B |
| CYTKCytokinetics | Stage 4, wk 2 | $62.99 | -0.5% | -17.6% | -27.8% | 55 | — | — | $8.8B |
| ARWRArrowhead Pharmaceuticals | Stage 4, wk 1 | $59.90 | -1.0% | -30.4% | -33.1% | 85 | — | — | $8.5B |
| PRAXPraxis Precision Medicines | Stage 4, wk 2 | $285.93 | -0.9% | -6.4% | -26.0% | 84 | — | — | $8.0B |
| ABVXAbivax SA | Stage 4, wk 6 | $86.59 | -2.8% | -30.6% | -40.4% | 44 | — | — | $7.6B |
| AXSMAxsome Therapeutics | Stage 4, wk 3 | $144.43 | +0.7% | -31.6% | -43.4% | 60 | — | — | $7.6B |
| IONSIonis Pharmaceuticals | Stage 4, wk 16 | $43.52 | -2.0% | -20.1% | -49.7% | 29 | — | — | $7.2B |
| LGNDLigand Pharmaceuticals | Stage 2, wk 2 | $322.75 | +1.7% | +10.5% | 0.0% | 92 | 32.4 | — | $6.5B |
| ORKAOruka Therapeutics | Stage 3, wk 4 | $96.87 | +0.2% | +2.2% | -14.3% | 98 | — | — | $6.4B |
| RYTMRhythm Pharmaceuticals | Stage 3, wk 6 | $92.57 | -0.5% | -9.9% | -21.3% | 40 | — | — | $6.4B |
| KODKodiak Sciences | Stage 2, wk 5 | $99.18 | -1.2% | +149.0% | -1.2% | 99 | — | — | $6.2B |
| BLTEBelite Bio | Stage 3, wk 2 | $154.74 | +3.0% | 0.0% | -20.1% | 88 | — | — | $6.2B |
| IMVTImmunovant | Stage 3, wk 6 | $29.17 | -1.6% | -24.3% | -35.1% | 79 | — | — | $6.0B |
| MANEVeradermics | — | $139.69 | -2.9% | +37.1% | — | — | — | — | $5.8B |
| CGONCG Oncology | Stage 3, wk 4 | $64.68 | +1.9% | -6.5% | -19.8% | 86 | — | — | $5.7B |
| MIRMMirum Pharmaceuticals | Stage 4, wk 5 | $85.00 | -1.6% | -18.7% | -33.9% | 70 | — | — | $5.5B |
| COGTCogent Biosciences | Stage 4, wk 5 | $31.02 | -2.9% | -20.2% | -27.6% | 94 | — | — | $5.4B |
| SRRKScholar Rock Holding | Stage 3, wk 6 | $43.90 | -0.6% | -4.3% | -26.9% | 86 | — | — | $5.3B |
| ERASErasca | Stage 3, wk 6 | $14.35 | -4.2% | -19.6% | -36.1% | 99 | — | — | $5.0B |
| PTCTPTC Therapeutics | Stage 4, wk 7 | $59.97 | -7.0% | -12.0% | -33.0% | 46 | — | — | $5.0B |
| CRSPCRISPR Therapeutics | Stage 2, wk 6 | $51.42 | -5.2% | +3.7% | -19.6% | 41 | — | — | $5.0B |
| DFTXDefinium Therapeutics | Stage 3, wk 6 | $36.33 | -4.3% | -13.1% | -25.0% | 98 | — | — | $4.9B |
| TVTXTravere Therapeutics | Stage 3, wk 2 | $50.39 | -0.4% | -8.3% | -25.4% | 90 | — | — | $4.7B |
| DNTHDianthus Therapeutics | Stage 3, wk 4 | $82.38 | -0.4% | -22.3% | -29.0% | 97 | — | — | $4.6B |
| EWTXEdgewise Therapeutics | Stage 3, wk 3 | $38.90 | 0.0% | +1.4% | -19.5% | 97 | — | — | $4.2B |
| LEGNLegend Biotech | Stage 4, wk 9 | $21.63 | -3.0% | +13.8% | -40.4% | 32 | — | — | $4.2B |
| ARQTArcutis Biotherapeutics | Stage 2, wk 2 | $32.07 | +0.3% | +23.6% | -2.3% | 74 | 146.4 | — | $4.0B |
| RLAYRelay Therapeutics | Stage 3, wk 5 | $18.35 | -5.8% | -2.3% | -11.6% | 97 | — | — | $4.0B |
| ABCLAbCellera Biologics | Stage 2, wk 22 | $12.27 | -6.2% | +110.5% | -17.2% | 96 | — | — | $4.0B |
| IOVAIovance Biotherapeutics | Stage 2, wk 20 | $8.48 | -11.3% | +96.3% | -42.9% | 99 | — | — | $3.8B |
| TNGXTango Therapeutics | Stage 3, wk 9 | $22.72 | +0.8% | -16.5% | -30.9% | 98 | — | — | $3.8B |
| XENEXenon Pharmaceuticals | Stage 4, wk 3 | $37.41 | -0.3% | -39.9% | -47.3% | 45 | — | — | $3.6B |
| IRONDisc Medicine | Stage 3, wk 6 | $80.84 | -2.4% | +5.9% | -14.1% | 50 | — | — | $3.6B |
| ACADACADIA Pharmaceuticals | Stage 3, wk 5 | $20.59 | -0.8% | -19.6% | -32.6% | 47 | 9.1 | — | $3.5B |
| TARSTarsus Pharmaceuticals | Stage 2, wk 6 | $74.85 | +0.9% | +22.1% | -17.5% | 62 | — | — | $3.5B |
| PBLSParabilis Medicines | — | $28.32 | -1.3% | -16.6% | — | — | — | — | $3.5B |
| VKTXViking Therapeutics | Stage 4, wk 4 | $27.28 | +1.6% | -16.3% | -35.2% | 38 | — | — | $3.5B |
| CELCCelcuity | Stage 4, wk 14 | $69.13 | -0.2% | -21.2% | -52.3% | 49 | — | — | $3.4B |
| ELVNEnliven Therapeutics | Stage 3, wk 5 | $44.25 | -1.8% | -23.8% | -27.6% | 94 | — | — | $3.2B |
| DYNDyne Therapeutics | Stage 4, wk 1 | $16.69 | -2.1% | -33.9% | -37.7% | 34 | — | — | $3.1B |
| TLXTelix Pharmaceuticals | Stage 3, wk 1 | $9.10 | -4.3% | -9.2% | -29.1% | 43 | 95.4 | — | $3.1B |
| IDYAIDEAYA Biosciences | Stage 3, wk 1 | $31.96 | -2.8% | -9.7% | -24.8% | 53 | — | — | $3.1B |
| DNLIDenali Therapeutics | Stage 4, wk 1 | $18.94 | -2.0% | -18.2% | -30.4% | 66 | — | — | $3.0B |
| NRIXNurix Therapeutics | Stage 3, wk 2 | $26.80 | -1.2% | +15.4% | -3.6% | 96 | 10.5 | — | $2.9B |
| MRVIMaravai LifeSciences Holdings | Stage 2, wk 26 | $7.81 | -7.7% | +21.7% | -13.2% | 97 | — | — | $2.9B |
| BEAMBeam Therapeutics | Stage 4, wk 7 | $27.23 | -5.6% | +5.1% | -28.2% | 61 | — | — | $2.8B |
| VRDNViridian Therapeutics | Stage 4, wk 2 | $24.67 | -0.5% | +27.8% | -27.0% | 59 | — | — | $2.8B |
| ZLABZai Lab | Stage 2, wk 11 | $22.07 | -1.3% | +21.4% | -18.3% | 44 | — | — | $2.7B |
| MBXMBX Biosciences | Stage 3, wk 4 | $55.87 | +2.4% | -13.3% | -21.0% | 98 | — | — | $2.7B |
| ADMAADMA Biologics | Stage 1, wk 12 | $11.41 | -2.9% | +30.5% | -44.0% | 35 | 15.6 | — | $2.6B |
| PGENPrecigen | Stage 2, wk 23 | $6.94 | +4.5% | +5.0% | -18.9% | 91 | — | — | $2.5B |
| CLDXCelldex Therapeutics | Stage 3, wk 5 | $30.10 | +0.7% | -20.1% | -32.9% | 66 | — | — | $2.4B |
| PHVSPharvaris | Stage 3, wk 4 | $33.53 | -0.1% | +4.0% | -13.7% | 86 | — | — | $2.4B |
| NAMSNewAmsterdam Pharma | Stage 4, wk 14 | $20.06 | -3.4% | -27.0% | -51.6% | 26 | — | — | $2.3B |
| BHVNBiohaven | Stage 3, wk 6 | $15.42 | -6.5% | +15.3% | -11.3% | 43 | — | — | $2.3B |
| RCUSArcus Biosciences | Stage 3, wk 6 | $18.19 | -2.3% | -34.1% | -42.4% | 46 | — | — | $2.3B |
| HRMYHarmony Biosciences Holdings | Stage 2, wk 18 | $38.76 | +0.4% | +8.9% | -9.6% | 77 | 11.6 | — | $2.3B |
| VERAVera Therapeutics | Stage 4, wk 12 | $30.98 | +1.5% | -3.9% | -44.4% | 58 | — | — | $2.2B |
| AUPHAurinia Pharmaceuticals | Stage 2, wk 5 | $16.65 | -3.3% | +14.3% | -10.6% | 79 | 7.6 | — | $2.2B |
| XNCRXencor | Stage 2, wk 15 | $29.82 | +2.1% | +53.7% | -0.6% | 95 | — | — | $2.2B |
| IMNMImmunome | Stage 4, wk 1 | $18.21 | -0.4% | -20.9% | -38.9% | 65 | — | — | $2.1B |
| LKFTLakefront Biotherapeutics | Stage 1, wk 3 | $32.28 | -0.2% | +20.7% | -6.8% | 57 | 3.0 | — | $2.1B |
| PVLAPalvella Therapeutics | Stage 3, wk 4 | $146.15 | -3.6% | +3.8% | -7.6% | 94 | — | — | $2.1B |
| VCELVericel | Stage 3, wk 7 | $40.26 | -6.2% | -12.6% | -16.7% | 65 | 90.8 | — | $2.1B |
| ZYMEZymeworks | Stage 2, wk 10 | $28.61 | -0.3% | +31.2% | -7.9% | 85 | — | — | $2.1B |
| FTREFortrea Holdings | Stage 2, wk 21 | $21.29 | -8.0% | +12.4% | -17.7% | 95 | — | — | $2.1B |
| SEPNSepterna | Stage 2, wk 21 | $44.00 | -2.7% | +25.8% | -8.7% | 95 | — | — | $2.1B |
| MESOMesoblast | Stage 4, wk 5 | $15.16 | -3.3% | +4.8% | -27.7% | 48 | — | — | $2.0B |
| SRPTSarepta Therapeutics | Stage 2, wk 4 | $18.62 | -3.2% | +17.3% | -23.8% | 39 | — | — | $2.0B |
| SLSSELLAS Life Sciences Group | Stage 3, wk 5 | $9.68 | -4.7% | -13.7% | -37.4% | 99 | — | — | $2.0B |
| BRVEBraveheart Bio | — | $21.51 | +1.5% | — | — | — | — | — | $1.9B |
| COAGHemab Therapeutics Holdings | — | $41.45 | +2.5% | -7.9% | — | — | — | — | $1.9B |
| TRVITrevi Therapeutics | Stage 3, wk 7 | $13.56 | -1.8% | -24.2% | -30.5% | 75 | — | — | $1.9B |
| VIRVir Biotechnology | Stage 2, wk 10 | $11.30 | -3.8% | +27.0% | -5.3% | 94 | — | — | $1.9B |
| ABSIAbsci | Stage 2, wk 4 | $11.13 | -8.0% | +40.4% | -8.0% | 97 | — | — | $1.9B |
| TRAXFirst Tracks Biotherapeutics | — | $45.08 | -0.3% | -2.3% | — | — | — | — | $1.9B |
| GENBGenerate Biomedicines | — | $14.46 | -8.3% | +0.8% | — | — | — | — | $1.9B |
| ZBIOZenas BioPharma | Stage 3, wk 4 | $28.39 | -1.3% | -8.8% | -34.2% | 55 | — | — | $1.9B |
| AGIOAgios Pharmaceuticals | Stage 2, wk 1 | $30.55 | -17.9% | 0.0% | -32.8% | 35 | — | — | $1.8B |
| MAZEMaze Therapeutics | Stage 1, wk 1 | $31.48 | -1.4% | +15.2% | -39.3% | 54 | — | — | $1.7B |
| NTLAIntellia Therapeutics | Stage 1, wk 3 | $12.47 | -5.7% | +15.8% | -30.1% | 50 | — | — | $1.7B |
| QUREuniQure | Stage 3, wk 5 | $24.83 | -1.9% | -43.6% | -63.4% | 17 | — | — | $1.7B |
| STOKStoke Therapeutics | Stage 4, wk 7 | $26.29 | -0.2% | -11.1% | -31.4% | 42 | — | — | $1.7B |
| REPLReplimune Group | Stage 2, wk 17 | $17.61 | +1.3% | +47.9% | 0.0% | 91 | — | — | $1.7B |
| KLRAKailera Therapeutics | — | $12.86 | -4.1% | -25.8% | — | — | — | — | $1.7B |
| NVAXNovavax | Stage 2, wk 6 | $10.08 | -3.7% | +36.0% | -21.4% | 69 | — | — | $1.7B |
| MLYSMineralys Therapeutics | Stage 4, wk 4 | $18.18 | -14.4% | -29.5% | -61.6% | 22 | — | — | $1.6B |
| URGNUroGen Pharma | Stage 3, wk 3 | $32.72 | -2.3% | -15.2% | -34.9% | 90 | — | — | $1.6B |
| NBTXNanobiotix | Stage 4, wk 2 | $31.37 | -7.2% | -19.3% | -43.0% | 91 | — | — | $1.6B |
| RAREUltragenyx Pharmaceutical | Stage 4, wk 7 | $16.10 | -4.1% | -35.7% | -55.9% | 22 | — | — | $1.6B |
| IMCRImmunocore Holdings | Stage 3, wk 5 | $30.49 | -2.5% | -6.0% | -24.2% | 48 | — | — | $1.6B |
| GPCRStructure Therapeutics | Stage 4, wk 7 | $21.87 | -0.3% | -54.8% | -76.7% | 36 | — | — | $1.6B |
| INVAInnoviva | Stage 4, wk 10 | $21.22 | -0.4% | +2.2% | -12.5% | 70 | 4.9 | — | $1.5B |
| OCULOcular Therapeutix | Stage 4, wk 2 | $6.97 | -4.7% | -17.0% | -56.7% | 29 | — | — | $1.5B |
| RAPPRapport Therapeutics | Stage 3, wk 5 | $25.05 | +3.5% | -38.6% | -52.3% | 47 | — | — | $1.5B |
| TYRATyra Biosciences | Stage 4, wk 11 | $21.07 | -1.9% | -34.2% | -46.8% | 80 | — | — | $1.4B |
| ANABAnaptysBio | Stage 3, wk 7 | $48.28 | -0.7% | -10.0% | -30.8% | 95 | — | — | $1.4B |
| GHRSGH Research | Stage 3, wk 5 | $20.86 | -3.0% | -26.0% | -31.9% | 86 | — | — | $1.4B |
| KRSAKorsana Biosciences | Stage 2, wk 27 | $30.14 | -0.3% | +23.4% | -32.5% | 96 | — | — | $1.4B |
| OMEROmeros | Stage 2, wk 11 | $18.44 | -2.7% | +46.8% | -12.4% | 97 | 13.8 | — | $1.3B |
| NKTRNektar Therapeutics | Stage 4, wk 3 | $38.87 | -0.8% | -44.9% | -61.3% | 31 | — | — | $1.3B |
| DMRADamora Therapeutics | Stage 4, wk 3 | $21.49 | -2.4% | -24.8% | -37.1% | 98 | — | — | $1.3B |
| KARDKardigan | — | $14.13 | -1.3% | -29.2% | — | — | — | — | $1.3B |
| LBRXLB Pharmaceuticals | Stage 3, wk 2 | $39.70 | -1.1% | -7.3% | -19.8% | 97 | 394.2 | — | $1.3B |
| SLNSilence Therapeutics | Stage 2, wk 2 | $19.75 | -0.3% | +84.9% | -0.3% | 98 | — | — | $1.2B |
| SNDXSyndax Pharmaceuticals | Stage 4, wk 7 | $13.65 | -3.5% | -29.1% | -45.7% | 56 | — | — | $1.2B |
| VORVor Biopharma | Stage 3, wk 3 | $19.68 | -5.9% | -8.1% | -21.6% | 37 | 0.1 | — | $1.2B |
| DRTSAlpha Tau Medical | Stage 2, wk 71 | $13.06 | -1.3% | +9.6% | -15.7% | 98 | — | — | $1.2B |
| VSTMVerastem | Stage 2, wk 8 | $9.75 | +0.9% | +71.4% | -8.4% | 62 | — | — | $1.2B |
| AVLNAvalyn Pharma | — | $25.63 | -0.3% | -10.1% | — | — | — | — | $1.1B |
| IMTXImmatics | Stage 4, wk 15 | $7.20 | -1.5% | -20.2% | -39.3% | 33 | — | — | $1.1B |
| SGPSpyGlass Pharma | — | $32.24 | -0.8% | +42.2% | — | — | — | — | $1.1B |
| JANXJanux Therapeutics | Stage 2, wk 10 | $17.47 | -2.0% | +14.0% | -49.7% | 30 | — | — | $1.1B |
| INBXInhibrx Biosciences | Stage 2, wk 9 | $71.78 | -2.5% | -13.2% | -49.4% | 48 | — | — | $1.1B |
| SPTXSeaport Therapeutics | — | $19.60 | -7.1% | -5.1% | — | — | — | — | $1.0B |
| MLTXMoonLake Immunotherapeutics | Stage 4, wk 7 | $11.78 | -6.3% | -32.3% | -46.8% | 71 | — | — | $1.0B |
| RIGLRigel Pharmaceuticals | Stage 2, wk 15 | $51.31 | -0.3% | +37.1% | -0.3% | 91 | 2.9 | — | $958M |
| ORICOric Pharmaceuticals | Stage 3, wk 1 | $9.24 | +2.8% | -12.8% | -36.9% | 34 | — | — | $958M |
| ODTXOdyssey Therapeutics | — | $19.54 | -1.5% | +7.8% | — | — | — | — | $939M |
| LTGOLatigo Biotherapeutics | — | $13.95 | -10.2% | — | — | — | — | — | $925M |
| CGEMCullinan Therapeutics | Stage 3, wk 3 | $15.03 | -2.7% | -7.5% | -34.5% | 94 | — | — | $924M |
| GLUEMonte Rosa Therapeutics | Stage 4, wk 8 | $10.76 | -1.0% | -30.0% | -57.5% | 43 | — | — | $918M |
| OBXObsidian Therapeutics | — | $14.79 | +1.9% | -22.1% | — | — | — | — | $914M |
| KURAKura Oncology | Stage 2, wk 19 | $10.26 | -2.8% | +11.6% | -24.5% | 54 | — | — | $913M |
| MGTXMeiraGTx Holdings | Stage 3, wk 5 | $9.49 | -2.2% | -20.1% | -36.6% | 58 | 11.2 | — | $911M |
| JBIOJade Biosciences | Stage 4, wk 3 | $14.06 | -1.3% | -26.6% | -47.6% | 85 | — | — | $894M |
| ANROAlto Neuroscience | Stage 3, wk 3 | $22.60 | -3.7% | -17.1% | -38.3% | 89 | — | — | $887M |
| AKTSAktis Oncology | Stage 4, wk 1 | $15.93 | -5.5% | -28.3% | — | — | — | — | $886M |
| ALMSAlumis | Stage 4, wk 7 | $6.73 | -2.3% | -74.2% | -77.8% | 83 | — | — | $871M |
| CRVSCorvus Pharmaceuticals | Stage 4, wk 6 | $10.03 | -2.0% | -25.0% | -60.7% | 76 | — | — | $844M |
| HELPHelus Pharma | Stage 2, wk 13 | $10.60 | -1.1% | +31.5% | -24.4% | 82 | — | — | $774M |
| DNAGinkgo Bioworks Holdings | Stage 2, wk 4 | $11.21 | -12.0% | +25.4% | -25.2% | 48 | — | — | $755M |
| OABIOmniAb | Stage 2, wk 22 | $5.11 | -2.3% | +160.7% | -3.2% | 98 | — | — | $745M |
| AVBPArriVent BioPharma | Stage 4, wk 2 | $14.87 | -6.8% | -49.8% | -57.2% | 39 | — | — | $733M |
| ACHVAchieve Life Sciences | Stage 2, wk 25 | $6.83 | -5.0% | +8.1% | -19.9% | 80 | — | — | $704M |
| ATTOAttovia Therapeutics | — | $15.19 | -0.5% | — | — | — | — | — | $693M |
| APMDApnimed | — | $16.40 | -5.4% | -34.4% | — | — | 2.6 | — | $683M |
| DSGNDesign Therapeutics | Stage 3, wk 6 | $10.68 | -3.4% | -16.3% | -33.0% | 90 | — | — | $668M |
| SLDBSolid Biosciences | Stage 3, wk 6 | $6.20 | -3.0% | -22.7% | -44.4% | 63 | — | — | $665M |
| FDMT4D Molecular Therapeutics | Stage 2, wk 31 | $11.90 | -6.9% | +17.9% | -29.0% | 57 | — | — | $657M |
| CADLCandel Therapeutics | Stage 3, wk 2 | $8.33 | -3.7% | -17.3% | -39.4% | 86 | — | — | $637M |
| AURAAura Biosciences | Stage 4, wk 1 | $6.14 | -2.5% | -12.8% | -31.0% | 54 | — | — | $637M |
| IMMXImmix Biopharma | Stage 3, wk 2 | $7.68 | -3.8% | -8.8% | -46.9% | 95 | — | — | $637M |
| ANLAdlai Nortye Group | Stage 3, wk 1 | $9.55 | -7.1% | -26.5% | -42.5% | 99 | — | — | $615M |
| OLMAOlema Pharmaceuticals | Stage 4, wk 7 | $7.00 | -4.5% | -37.9% | -80.5% | 40 | — | — | $612M |
| ZVRAZevra Therapeutics | Stage 3, wk 11 | $10.28 | -0.8% | +2.2% | -30.3% | 55 | 11.2 | — | $610M |
| BCAXBicara Therapeutics | Stage 4, wk 2 | $9.13 | -6.2% | -64.5% | -70.0% | 27 | — | — | $604M |
| NVCTNuvectis Pharma | Stage 3, wk 1 | $18.48 | -0.5% | -14.4% | -35.2% | 98 | — | — | $603M |
| DBVTDBV Technologies | Stage 4, wk 17 | $9.49 | -7.8% | -30.1% | -61.3% | 30 | — | — | $596M |
| CLYMClimb Bio | Stage 3, wk 4 | $10.25 | -0.8% | -13.2% | -42.5% | 99 | — | — | $589M |
| STTKShattuck Labs | Stage 3, wk 5 | $5.56 | -2.8% | -23.7% | -31.0% | 98 | — | — | $558M |
| NGNENeurogene | Stage 3, wk 5 | $27.55 | -4.4% | -16.2% | -35.7% | 42 | — | — | $551M |
| DRUGBright Minds Biosciences | Stage 4, wk 6 | $54.98 | -3.0% | -25.5% | -42.7% | 55 | — | — | $542M |
| PBYIPuma Biotechnology | Stage 2, wk 70 | $10.44 | -0.9% | +35.8% | -7.3% | 95 | 22.1 | — | $539M |
| OCSOculis Holding | Stage 4, wk 7 | $8.26 | +0.2% | -30.5% | -74.7% | 19 | — | — | $509M |
| SRZNSurrozen | Stage 1, wk 4 | $29.04 | -1.4% | +33.3% | -14.9% | 96 | — | — | $508M |
| ARVNArvinas | Stage 4, wk 4 | $7.86 | -0.5% | -2.5% | -43.2% | 40 | 29.7 | — | $507M |
| CBIOCrescent Biopharma | Stage 4, wk 1 | $13.48 | -4.2% | -9.3% | -50.0% | 60 | — | — | $501M |
| DMACDiaMedica Therapeutics | Stage 2, wk 3 | $9.25 | -2.8% | +41.9% | -5.8% | 80 | — | — | $499M |
| FTHFaeth Therapeutics | Stage 3, wk 3 | $18.69 | -0.3% | -31.6% | -53.3% | 95 | — | — | $483M |
| RGNXREGENXBIO | Stage 4, wk 7 | $7.20 | -2.8% | -27.7% | -54.9% | 27 | — | — | $475M |
| MNPRMonopar Therapeutics | Stage 3, wk 5 | $70.32 | -2.2% | -37.0% | -43.2% | 42 | — | — | $472M |
| PHATPhathom Pharmaceuticals | Stage 4, wk 20 | $5.74 | -7.7% | -36.1% | -68.3% | 20 | — | — | $467M |
| EPRXEupraxia Pharmaceuticals | Stage 2, wk 4 | $6.83 | -5.8% | +4.9% | -24.9% | 73 | — | — | $451M |
| CRMDCorMedix | Stage 3, wk 3 | $5.70 | -25.5% | -24.6% | -55.3% | 24 | 4.0 | — | $444M |
| BLSMBlossomHill Therapeutics | — | $13.75 | -9.6% | — | — | — | — | — | $437M |
| PRTAProthena | Stage 4, wk 6 | $8.47 | -4.6% | +1.7% | -26.4% | 39 | — | — | $435M |
| MPLTMapLight Therapeutics | Stage 4, wk 8 | $7.58 | -1.8% | -39.6% | -81.0% | 22 | — | — | $421M |
| YDESYD Bio | Stage 1, wk 9 | $5.94 | +1.2% | +158.3% | -61.5% | 22 | — | — | $421M |
| ASMBAssembly Biosciences | Stage 4, wk 2 | $20.13 | -3.5% | -20.6% | -47.7% | 31 | 19.5 | — | $410M |
| TECXTectonic Therapeutic | Stage 4, wk 2 | $19.78 | -3.5% | -29.2% | -47.9% | 58 | — | — | $387M |
| AVTXAvalo Therapeutics | Stage 4, wk 2 | $7.17 | -3.6% | -60.3% | -68.6% | 19 | — | — | $385M |
| CAPRCapricor Therapeutics | Stage 1, wk 1 | $6.38 | -3.8% | +51.9% | -81.9% | 48 | — | — | $371M |
| AGMBAgomAb Therapeutics NV | — | $7.49 | -5.8% | -44.6% | — | — | — | — | $369M |
| FENCFennec Pharmaceuticals | Stage 3, wk 1 | $10.24 | -6.5% | +6.8% | -19.9% | 70 | — | — | $359M |
| OBIOOrchestra BioMed Holdings | Stage 2, wk 10 | $5.91 | -3.0% | +43.4% | -6.9% | 89 | — | — | $355M |
| CTNMContineum Therapeutics | Stage 4, wk 2 | $9.39 | +0.6% | -41.1% | -46.6% | 43 | — | — | $353M |
| KYTXKyverna Therapeutics | Stage 4, wk 7 | $5.67 | -3.1% | -24.5% | -49.6% | 38 | — | — | $351M |
| TTRXTurn Therapeutics | Stage 2, wk 14 | $10.43 | -2.7% | +18.0% | -32.0% | 95 | — | — | $317M |
| ARCTArcturus Therapeutics Holdings | Stage 2, wk 10 | $11.03 | -9.2% | +83.8% | -34.8% | 66 | — | — | $314M |
| ENTAEnanta Pharmaceuticals | Stage 4, wk 6 | $10.71 | -3.9% | -17.3% | -36.4% | 54 | — | — | $312M |
| AGENAgenus | Stage 3, wk 1 | $6.84 | -3.5% | -12.5% | -31.1% | 92 | 2.6 | — | $309M |
| BNTCBenitec Biopharma | Stage 4, wk 4 | $8.74 | -1.0% | -28.1% | -46.6% | 26 | — | — | $305M |
| VOGXVogenx | — | $20.25 | +1.7% | — | — | — | — | — | $301M |
| SCTXScribe Therapeutics | — | $15.42 | -11.6% | -26.0% | — | — | — | — | $292M |
| EIKNEikon Therapeutics | — | $5.31 | -0.7% | -42.0% | — | — | — | — | $288M |
| LYELLyell Immunopharma | Stage 4, wk 6 | $11.04 | -2.3% | -14.2% | -71.4% | 32 | — | — | $271M |
| QTTBQ32 Bio | Stage 3, wk 6 | $8.91 | +0.5% | -41.2% | -58.3% | 98 | 2.8 | — | $265M |
| GLSIGreenwich LifeSciences | Stage 1, wk 4 | $17.41 | -8.4% | +28.6% | -48.1% | 94 | — | — | $256M |
| EVMNEvommune | Stage 4, wk 10 | $6.73 | -1.2% | -41.9% | — | — | — | — | $244M |
| SLGLSol-Gel Technologies | Stage 4, wk 3 | $68.35 | -0.5% | -16.6% | -30.2% | 93 | — | — | $224M |
| KROSKeros Therapeutics | Stage 1, wk 9 | $11.04 | -2.8% | +9.2% | -49.5% | 35 | — | — | $219M |
| KRROKorro Bio | Stage 4, wk 3 | $14.32 | +0.8% | +33.3% | -65.0% | 18 | — | — | $211M |
| DTILPrecision BioSciences | Stage 3, wk 6 | $7.06 | -5.1% | 0.0% | -23.9% | 42 | — | — | $195M |
| ACOGAlpha Cognition | Stage 2, wk 18 | $8.74 | -4.9% | +3.7% | -10.4% | 78 | — | — | $190M |
| YARWYarrow Bioscience | Stage 3, wk 3 | $19.90 | -0.5% | -40.8% | -53.7% | 95 | — | — | $185M |
| MDWDMediWound | Stage 4, wk 40 | $13.30 | -4.0% | -6.5% | -31.3% | 35 | — | — | $172M |
| CUECue Biopharma | Stage 3, wk 5 | $20.87 | -2.7% | -22.3% | -44.8% | 54 | — | — | $152M |
| STROSutro Biopharma | Stage 4, wk 7 | $9.10 | -0.4% | -63.7% | -77.8% | 44 | — | — | $151M |
| RNAAtrium Therapeutics | — | $8.27 | +0.1% | -27.0% | — | — | — | — | $141M |
| SPRBSpruce Biosciences | Stage 4, wk 2 | $46.39 | -0.9% | +7.5% | -63.5% | 19 | — | — | $133M |
| IMUXImmunic | Stage 4, wk 2 | $7.51 | -3.7% | -46.7% | -55.6% | 49 | — | — | $102M |
| KZIAKazia Therapeutics | Stage 4, wk 1 | $8.50 | -2.5% | -31.5% | -49.7% | 62 | — | — | $97.1M |
| TNXPTonix Pharmaceuticals Holding | Stage 4, wk 6 | $5.10 | -3.4% | -52.2% | -74.4% | 14 | — | — | $87.5M |
| GOSSGossamer Bio | Stage 4, wk 34 | $10.38 | -2.9% | -25.4% | -96.6% | 5 | — | — | $63.5M |
| IRLAIRulya Therapeutics | Stage 2, wk 4 | $32.95 | +4.2% | +32.0% | -62.6% | 49 | — | — | $33.5M |
| BOLTBolt Biotherapeutics | Stage 1, wk 2 | $6.59 | +3.6% | +65.6% | -7.1% | 63 | — | — | $15.5M |
Biotechnology Stocks: quick answers
How many biotechnology stocks are in an uptrend?
As of Oct 30, 2026, 60 of the 238 US-listed biotechnology stocks we cover are in Stage 2, the uptrend phase, including Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Moderna (MRNA), BeOne Medicines (ONC) and Royalty Pharma (RPRX).
What is the largest biotechnology stock?
Vertex Pharmaceuticals (VRTX), with a market value of $142B. It closed at $558.88 on Oct 30, 2026, in Stage 2.
Which biotechnology stocks are near their 52-week high?
As of Oct 30, 2026, 6 are within 5% of a 52-week high: Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), BeOne Medicines (ONC), Royalty Pharma (RPRX), Genmab (GMAB) and Exelixis (EXEL).
End-of-day data for common stocks and ADRs on the NYSE, Nasdaq and NYSE American, computed after each US close and dated to the trading session.